Genetically modified T cells in cancer therapy: opportunities and challenges
Tumours use many strategies to evade the host immune response, including downregulation or weak immunogenicity of target antigens and creation of an immune-suppressive tumour environment. T cells play a key role in cell-mediated immunity and, recently, strategies to genetically modify T cells either...
Main Authors: | Michaela Sharpe, Natalie Mount |
---|---|
Format: | Article |
Language: | English |
Published: |
The Company of Biologists
2015-04-01
|
Series: | Disease Models & Mechanisms |
Subjects: | |
Online Access: | http://dmm.biologists.org/content/8/4/337 |
Similar Items
-
Tracking the CAR-T Revolution: Analysis of Clinical Trials of CAR-T and TCR-T Therapies for the Treatment of Cancer (1997–2020)
by: Nikola A. Ivica, et al.
Published: (2021-08-01) -
Engineered T Cell Therapy for Gynecologic Malignancies: Challenges and Opportunities
by: Yifan Xu, et al.
Published: (2021-07-01) -
Engineered T Cell Therapy for Cancer in the Clinic
by: Lijun Zhao, et al.
Published: (2019-10-01) -
T-Cell Gene Therapy in Cancer Immunotherapy: Why It Is No Longer Just CARs on The Road
by: Michael D. Crowther, et al.
Published: (2020-06-01) -
Identification and Clinical Application of Immunological Receptors Targeting Mutated Antigens Expressed by Solid Tumors
by: Anna Pasetto
Published: (2020-09-01)